These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34844283)

  • 1. Continuous glucose monitoring systems for monitoring cystic fibrosis-related diabetes.
    Toner A; McCloy A; Dyce P; Nazareth D; Frost F
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013755. PubMed ID: 34844283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug treatments for managing cystic fibrosis-related diabetes.
    Onady GM; Stolfi A
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD004730. PubMed ID: 33075159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.
    Aslam AA; Higgins C; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD012040. PubMed ID: 28102546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis.
    Dawson S; Girling CJ; Cowap L; Clark-Carter D
    Cochrane Database Syst Rev; 2023 Mar; 3(3):CD013766. PubMed ID: 36989170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exercise versus airway clearance techniques for people with cystic fibrosis.
    Heinz KD; Walsh A; Southern KW; Johnstone Z; Regan KH
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD013285. PubMed ID: 35731672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin and oral agents for managing cystic fibrosis-related diabetes.
    Onady GM; Stolfi A
    Cochrane Database Syst Rev; 2016 Apr; 4():CD004730. PubMed ID: 27087121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.
    Aslam AA; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2023 Mar; 3(3):CD012040. PubMed ID: 36866921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing of pancreatic enzyme replacement therapy (PERT) in cystic fibrosis.
    Ng C; Major G; Smyth AR
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD013488. PubMed ID: 34339047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interventions for improving adherence to airway clearance treatment and exercise in people with cystic fibrosis.
    Jones M; Moffatt F; Harvey A; Ryan JM
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD013610. PubMed ID: 37462324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin A and beta (β)-carotene supplementation for cystic fibrosis.
    de Vries JJ; Chang AB; Bonifant CM; Shevill E; Marchant JM
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006751. PubMed ID: 30091146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autogenic drainage for airway clearance in cystic fibrosis.
    McCormack P; Burnham P; Southern KW
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009595. PubMed ID: 28984368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrolide antibiotics (including azithromycin) for cystic fibrosis.
    Southern KW; Solis-Moya A; Kurz D; Smith S
    Cochrane Database Syst Rev; 2024 Feb; 2(2):CD002203. PubMed ID: 38411248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-acting inhaled bronchodilators for cystic fibrosis.
    Smith S; Rowbotham NJ; Edwards CT
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD013666. PubMed ID: 35749226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant growth hormone therapy for cystic fibrosis in children and young adults.
    Thaker V; Carter B; Putman M
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD008901. PubMed ID: 34424546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respiratory muscle training for cystic fibrosis.
    Stanford G; Ryan H; Solis-Moya A
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD006112. PubMed ID: 33331663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.
    Lo DK; Muhlebach MS; Smyth AR
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD009650. PubMed ID: 30030966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory muscle training for cystic fibrosis.
    Hilton N; Solis-Moya A
    Cochrane Database Syst Rev; 2018 May; 5(5):CD006112. PubMed ID: 29797578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.